Dade Behring (Deerfield, Illinois), the University of Frankfurt (Frankfurt, Germany) and Innovectis (also Frankfurt) have signed an exclusive license agreement that provides Dade Behring with worldwide rights for the inventions of a research group at the university that relate to placental growth factor (PlGF) for cardiovascular diseases, soluble CD40 ligand for the prognosis of the course of disease in acute coronary syndrome (ACS), and additional markers for cardiovascular diseases.